The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...
Salk scientists identify protein BCL6 as a key regulator of muscle maintenance in mice; BCL6-enhancing therapies may prevent ...
A groundbreaking study has shown that a drug currently being tested for ovarian and bile duct cancer, called NXP800, could ...
Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.
Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...
Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone therapy enzalutamide.
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...
Corcept Therapeutics' long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant. Click here to read ...
Your doctor may recommend chemo, hormone, or targeted therapy ... pathways that are critical to tumor growth. These oral or intravenous (IV) administered drugs “target” cancerous cells ...
The analysis covers Hormone Sensitive Advanced Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps ...